Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862741 | 0.82 | GRIN2D (0.33) | MAPK1MEN1HTTKMT2ALMNA | |
| SCHEMBL113455 | 0.80 | MAPK1 (0.44) | GPR35TSHRMAPK1ALDH1A1AHR | |
| SCHEMBL29445407 | 0.80 | MAPK1 (0.44) | GPR35TSHRMAPK1ALDH1A1AHR | |
| SCHEMBL2325803 | 0.80 | MAP4K4 (0.43) | TSHRMAPK1ALDH1A1MAPTKDM4E | |
| SCHEMBL9317984 | 0.79 | CRHBP (0.46) | MAPK1ALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL2178791 | 0.78 | ALDH1A1 (0.50) | GPR35TSHRMAPK1ALDH1A1AHR | |
| SCHEMBL203312 | 0.78 | INPPL1 (0.46) | TSHRMAPK1ALDH1A1CYP3A4AHR | |
| SCHEMBL30557784 | 0.78 | ALDH1A1 (0.50) | GPR35TSHRMAPK1ALDH1A1AHR | |
| SCHEMBL12161659 | 0.78 | MAPK1 (0.42) | GPR35TSHRMAPK1ALDH1A1AHR | |
| SCHEMBL15227574 | 0.77 | MAPK1 (0.41) | GPR35TSHRMAPK1ALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101830845-A | Synthesis method of 5-chloro-2,3-dihydroxyl pyridine | NANJING DAHAI PHARMACEUTICAL CO LTD | 2010-09-15 | — | — | CN | claimed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-118525021-A | MALT 1-targeted proteolytic compounds | 上海齐鲁制药研究中心有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023143249-A1 | PROTEIN DEGRADATION COMPOUND TARGETING MALT1 | 上海齐鲁制药研究中心有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-108473499-B | Novel pyrazolopyrimidine derivatives | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-11 | — | — | US | disclosed |
| EP-0483061-B1 | Process for the preparation of 4-(3-fluoro-pyridine-2-yloxy)-phenoxy-propionic acids | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | EP | disclosed |
| US-5274100-A | Process for the preparation of (3-fluoropyridin-2-yloxy)phenoxypropionic acids | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0526093-A1 | New non-steroidal agents as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0483061-A2 | Process for the preparation of 4-(3-fluoro-pyridine-2-yloxy)-phenoxy-propionic acids | CIBA-GEIGY AG (CH) | 1992-04-29 | — | — | EP | disclosed |
| CN-1053065-A | AZAOXINDOLE DERIVATIVES | PFIZER (US) | 1991-07-17 | — | — | CN | disclosed |
| WO-1991009598-A1 | AZAOXINDOLE DERIVATIVES | PFIZER INC. (US) | 1991-07-11 | — | — | WO | disclosed |
| EP-0436333-A2 | Azaoxindole derivatives | PFIZER INC. (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | GPR35 4211/4885TSHR 4112/4885MAPK1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.